FP
ASND icon

Financial Perspectives’s Ascendis Pharma A/S ASND Stock Holding History

Financial Perspectives’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-57
Closed -$7.5K – 643
2021
Q2 		$7.5K Sell
57
-7,289
-99% -$971K ﹤0.01% 493
2021
Q1 		$57K Buy
7,346
+7,289
+12,788% +$1.11M ﹤0.01% 549
2020
Q4 		$9.51K Buy
+57
New +$9.43K 0.01% 412

Other funds holding ASND

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Financial Perspectives's ASND Position: Q3 2021 in Review

Financial Perspectives sold out of Ascendis Pharma A/S (ASND) in Q3 2021, closing a stake of 57 shares — an estimated $7.5K sold.

Financial Perspectives first reported a position in ASND in Q4 2020 and held it in 3 quarters. The position peaked at $57K in Q1 2021. 166 funds tracked by Wall St. Rank hold ASND as of Q3 2021.

  • Financial Perspectives reported no remaining Ascendis Pharma A/S position as of Q3 2021 after selling out during the quarter.
  • Financial Perspectives sold 57 Ascendis Pharma A/S shares in Q3 2021, an estimated $7.5K.
  • Financial Perspectives first reported a position in Ascendis Pharma A/S in Q4 2020 and held it in 3 quarters.
  • Financial Perspectives's Ascendis Pharma A/S position peaked at $57K in Q1 2021.
  • 166 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2021.

Based on Financial Perspectives's 13F filing for Q3 2021, filed 10 Jan 2024.